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Abstract
Background: While the numbers of hepatitis-C-virus (HCV) infections among men who have sex with men (MSM)
who are co-infected with the human immunodeficiency virus (HIV) are on the rise, with vast evidence for sexual
transmission of HCV in this population, concerns have also been raised regarding sexual HCV-transmission among
MSM without HIV infection. Therefore, the aim of this study was to estimate the prevalence of hepatitis C among
MSM without HIV diagnosis in Zurich (Switzerland).
Methods: Participants were recruited from a gay health centre and various locations such as dark rooms, saunas
and cruising areas in Zurich. Participants self-completed a questionnaire assessing known and suspected risk factors
for HCV-infection, and provided a blood sample for detection of past (antibodies) and present (core antigen, RNA)
infections with HCV.
Results: In total, 840 MSM aged 17-79 (median: 33 years) underwent HCV-testing and completed the questionnaire,
among whom 19 reported living with HIV. Overall, seven tested positive for HCV-antibodies, and two were also
positive for HCV core antigen and HCV-RNA–these two were immigrants, one from a country where HCV is
endemic. None of the seven were aware of their infection. The seroprevalence of hepatitis C among the 821
non-HIV-diagnosed MSM was 0.37% (95%-CI: 0.12-1.69%), and one man harboured replicating virus (0.12%; 0.02-0.69%),
resulting in a number needed to test of 821 to detect one active infection. Significant univariable associations of lifetime
HCV-infection were found with known HIV-diagnosis (OR=72.7), being tattooed (OR=10.4), non-injection use of cocaine/
amphetamines (OR=8.8), and non-Swiss origin (OR=8.5). For MSM without HIV-diagnosis, the only variable marginally
associated with positive HCV-serostatus was being tattooed (OR=8.3). No significant associations were observed with
reported injection drug use, unprotected anal intercourse, sexual practices that may lead to mucosal trauma, or proxy
measures for group sex and lesion-prone STIs.
Conclusions: Our findings suggest that in Switzerland, hepatitis C among MSM without diagnosed HIV is not more
prevalent than in the general population. We found no evidence of elevated rates of sexual transmission of HCV
among MSM without HIV-infection. Therefore, we currently see no reason for promoting HCV-testing among all MSM
in Switzerland.
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Background
In Switzerland, a yearly average of 1500 new diagnoses
of active hepatitis C virus (HCV) infections (positive for
HCV core antigen and PCR) was reported for the years
2010-2012 (18.7/100000 inhabitants) [1]. The number
of people in Switzerland living with HCV is difficult to
estimate; however the proportion exposed to the virus
(anti-HCV prevalence) has been estimated to be 0.7%-1.0%,
based on testing blood donors and pregnant women [2].
Models that take the non-representativeness of these sub-
populations into account have suggested that the true anti-
HCV prevalence in the Swiss general population might be
between 1.25% and 1.75% [3]. 75% of individuals infected
with HCV develop chronic infection, which is linked to
the development of hepatic fibrosis, cirrhosis and he-
patocellular carcinoma [4].
Percutaneous exposures to blood, such as blood trans-
fusion, injection drug use (IDU), unsterile tattooing and
body piercings are well-established primary sources of
HCV infection [5,6], and there is increasing evidence
that non-injection drug use (NIDU) such as intranasal
cocaine is an independent risk factor for hepatitis C. There
is vast evidence that hepatitis C is extremely rarely trans-
mitted via sexual contact among HCV-serodiscordant
heterosexual couples [7-11]. However, in the last decade,
outbreaks of HCV-infection have been documented among
HIV-positive men who have sex with men (MSM) [12-22].
Data from the CASCADE study, including HIV-infected
MSM from eleven HIV seroconverter cohorts in eight
European countries and one such cohort in Canada [23],
showed that HCV incidence increased 4-to 6-fold between
1995 and 2007. Also, a recent Swiss HIV Cohort Study
(SHCS) publication has demonstrated that HCV incidence
increased 18-fold among HIV-positive MSM between 1998
and 2011 [24].
The exact modes of non-IDU related HCV transmission
among HIV positive MSM are still a matter of debate.
While several studies have identified group sex, traumatiz-
ing sexual practices, and receptive fisting as risk factors
for hepatitis C, and while there is little doubt that sexual
practices involving blood contact can facilitate transmis-
sion of a blood-borne virus such as HCV [13,18,25], the
role of contaminated seminal fluid for HCV transmission
is still debated [6,25-29]. Lately, a few cases of possibly
sexually acquired HCV infection among MSM without
HIV infection have been reported in the Netherlands [30],
and concerns have been raised that the HCV epidemic
among HIV-positive MSM could expand to MSM without
HIV infection [31]. MSM as such are often considered to
be at higher risk for HCV compared to the heterosexual
general population, and some authors have recommended
routine screening of MSM in Switzerland [32,33].
Very little is known about the prevalence of HCV in
non-HIV-positive MSM living in Switzerland, as there is
a dearth of systematic epidemiologic studies. Notification
forms in Switzerland include the gender of sexual partners,
but no MSM-specific epidemiological data have been pub-
lished. Such analyses from Germany have shown that HCV
notifications for MSM have been increasing over the last
decade; however, as is the case in Swiss surveillance, data
on HIV serostatus are not routinely collected as part of
German hepatitis C notification [34]. Therefore the aim of
the present study was to narrow this gap by estimating the
prevalence of current and past HCV infection among non-
HIV-diagnosed MSM in Switzerland and–if applicable–to
identify potential risk factors for HCV infection.
Methods
Recruitment
Checkpoint Zurich is a gay health project run by gay
men that started in 2006. Clients can test for HIV and
syphilis (using rapid point of care tests) and for asymp-
tomatic bacterial sexually transmitted infections (STIs)
such as pharyngeal and rectal gonorrhoea or chlamydiosis.
Checkpoint Zurich employs medical staff for hepatitis
A and B vaccinations, clinical examinations, medical
counselling, post-exposure prophylaxis to prevent HIV
infection, and medical treatment for HIV and other
STIs. In 2007, Checkpoint Zurich initiated new outreach
strategies (“Checkpoint Mobile”) across various locations
(dark rooms, saunas, motorway rest stops, and private sex
parties), offering on-site testing for HIV and/or syphilis
[35]. Overall, both services demonstrated high levels of
acceptance and demand in the Swiss MSM community.
From January 2009 to July 2010, MSM clients visiting
Checkpoint Zurich to test for HIV and/or syphilis, and
MSM approached through Checkpoint Mobile were asked
to participate in the present study. After obtaining detailed
study information by specially trained male gay nurses
or fieldworkers, and after providing written consent to
be tested for these infections, participants self-completed
an anonymous paper and pencil questionnaire covering
detailed sexual practices, other potential exposures for
HCV infection such as injection drug use (IDU) or non-
injection drug use (NIDU) of cocaine/amphetamines,
tattoos, piercings, previous blood transfusions, and previ-
ous diagnosis of HIV or other STIs. All men provided a
venous blood sample, to be used for syphilis and HIV
rapid tests (at Checkpoint Zurich) and subsequently sent
to the University Hospital of Zurich for HCV screening.
While HCV-testing was free of charge, 30 Swiss Francs
was charged for the combined HIV and syphilis test.
Participants were given a printed single identifier to
use when calling Checkpoint Zurich to receive their test
results for hepatitis C (or, in the case of Checkpoint Mobile
clients, to use when receiving personal post-test HIV coun-
selling at Checkpoint Zurich). In case of positive test results
for any of the three infections, participants were offered
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further assistance, information and psychological support
and treatment at Checkpoint Zurich, if indicated.
Serology
HCV-screening was performed at the Clinic of Immunology,
University Hospital of Zurich, by parallel testing for anti-
bodies against HCV and HCV core antigen (ARCHITECT®
Anti-HCV; and ARCHITECT® HCV Ag; Abbott, Wiesbaden,
Germany). All specimens that were reactive or borderline
reactive for either antigen or antibody were confirmed by
quantitative HCV PCR (COBAS® AmpliPrep/ COBAS®
TaqMan® HCV, v2.0, Roche Basel, Switzerland). HIV
and Syphilis rapid test results were not entered into
the database and are thus not reported in this analysis.
Self-reported measures
As on-site recruitment required efficient data collec-
tion, questions were kept simple, mostly with binary
response options.
HIV status was queried as “positive”, “negative”,
“unknown” and “I don’t want to say”. For their lifetime
history of STI diagnoses, participants could indicate
whether they had had syphilis, urethral gonorrhoea, rectal
gonorrhoea, pharyngeal gonorrhoea, chlamydial infection,
genital herpes, genital or anal warts, hepatitis A, hepatitis B,
hepatitis C, and “others”. Where appropriate, colloquialisms
for STIs were used.
Drug use was queried as “Do you use injection drugs?”,
“Do you take cocaine/speed?”, “… ecstasy”, “… cannabis”,
“… poppers”. As for other known exposure risks for HCV
infection, participants could indicate if they had had a
blood transfusion prior to 1985, been tattooed, pierced,
had their penis pierced, and whether tattooing or piercing
was performed in Switzerland or abroad.
Unprotected anal intercourse (UAI) was queried as
“Do you practice unprotected anal intercourse?”, and answer
options (Yes/No) referred to “with my steady partner”, “with
known casual partners”, and “with anonymous partners”.
To address bleeding associated with sexual inter-
course, a filter question was included asking whether
participants engaged in “hard” sexual practices that
may lead to bleeding. This filter question was followed
by a list of various sexual behaviours, to be checked as
active and/or passive, including fisting, whipping,
genital torture, dildo usage and anal dilatation, enema
and catheterisation. It was further asked where and
with what type of sexual partner “hard” sexual practices
were performed.
Constructed measures
Participants’ countries of origin were grouped accord-
ing to the latest published data on prevalence of HCV-
antibodies in the general population: <1.5%; 1.5-3.5%
(including Switzerland); >3.5% [36].
To construct a proxy measure for STIs that have been
associated with HCV transmission in other studies [29]
we combined lifetime history of syphilis, rectal gonorrhoea,
and chlamydial infection, and labelled this proxy measure
“lesion-prone STIs”.
We constructed a proxy measure for “group sex” by
combining (a) reports of 10 or more sexual partners in the
past 12 months with (b) reports of engaging in “hard”
practices (see above) in sex clubs or at private sex parties.
Statistical analyses
Except for age and the number of sexual and UAI partners
in the last 12 months, all variables were either originally
binary or later dichotomized. Fisher’s exact test was used
to compare groups of men with and without HCV-
antibodies, as the number of men with HCV was below
20. For all analyses, a p value less than 0.05 or odds ratios
(OR) with a 95% confidence interval (CI) not including “1”
were considered statistically significant. Under the as-
sumption that HCV seroprevalence in this sample was 1%
and that 10% of HCV negative men had been exposed to
HCV transmission, power calculations showed the study
would have a power of 80% to detect an OR of 6.0 for the
association of HCV seropositivity with risky behaviour.
Power calculations were performed with G*Power 3.1
[37]. Confidence intervals of proportions were calculated
according to Newcombe et al. 1998 [38]. All other analyses
were performed using IBM® SPSS® Statistics, Version 20.
Ethical approval
The Ethics Commission of the Canton of Zurich,
Switzerland, approved the study (EK-1715); and further
approval for Checkpoint Mobile recruitment was obtained
from the owners and operators of the targeted locations.
Results
Study participants
Out of 884 men approached, 845 (95.6%) provided a blood
sample and informed consent regarding HCV-testing, and
usage of their anonymous data for scientific purposes. Five
questionnaires were excluded due to missing values in 5
or more key variables; the analytic sample thus consisted
of n = 840 study participants (95.0%).
No information was systematically collected as to
whether clients were recruited at Checkpoint Zurich or
via Checkpoint Mobile; however, field workers estimate
that the latter accounted for one quarter of participants.
Nineteen individuals (2.3% of the analytic sample) re-
ported a diagnosis of HIV; and of the remaining 821
men without known HIV infection, 579 (70.5%) were
self-reportedly HIV-negative, 188 (22.9%) said they did
not know their current HIV status, and 54 (6.6%) did
not want to disclose it. Socio-demographic and other health
and behaviour-related characteristics of study participants
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are shown in Table 1, both for the total sample and separ-
ately for men with and without HIV diagnosis. Participants’
age ranged from 17 to 79 years with a median of 33 years.
178 (21.2%) had a country of origin other than Switzerland;
and 9 (1.1%) originated from countries where HCV is
endemic (>3.5%–including four men from China and
three from Turkey).
Blood transfusions prior to 1985 were reported by 11
men (1.3%) and solely by individuals born before 1980,
underlining the plausibility of the answers given. The
question on IDU garnered the highest number of miss-
ing responses (n = 176; 21%); however this missingness
was equally distributed across HIV diagnosis and HCV
infection, respectively.
Except for blood transfusion and piercing, all suspected
HCV-related risk factors such as IDU, NIDU (particularly
consumption of cocaine/amphetamines), receptive fisting,
UAI with anonymous partners, as well as proxy measures
for group sex and lesion-prone STIs were more pronounced
among HIV-diagnosed MSM (Table 1).
Prevalence of hepatitis C and number needed to test
Evidence for acute or chronic infection with HCV was
found in 2 individuals (positive for HCV antibodies, HCV
antigen and HCV PCR), and 5 individuals had cleared their
infection (positive for HCV antibodies but negative for
HCV antigen and HCV PCR), resulting in an overall
anti-HCV prevalence of 0.83% (n = 7; 95%-CI: 0.40-1.71%).
None of the 7 individuals with HCV antibodies reported
a diagnosis of hepatitis C in the past–suggesting they
were unaware of their (past) infection, and suggesting
that clearance of HCV infection was spontaneous and
not due to medical treatment.
Among MSM not diagnosed with HIV, one individual
showed evidence of active (acute or chronic) HCV infec-
tion, and two had spontaneously cleared their infection,
resulting in an anti-HCV prevalence of 0.37% (n = 3; 95-CI:
0.12-1.07%). The number of non-HIV-diagnosed MSM
Checkpoint clients needed to test in order to detect one
active HCV infection (NNT) was 821 (95%-CI: 146-4545).
Among all participants, 450 (53.6%) reported at least
one of the following: NIDU of cocaine/amphetamines,
being tattooed, being pierced, receptive fisting, group sex
(proxy measure), or a history of lesion-prone STIs. If only
this sub-group were to be screened for HCV, the NNT
would be reduced to 225 individuals (95%-CI: 62-820).
However with HIV-diagnosed MSM excluded from this
sub-group, the NNT would be 433 (77-2439). Figure 1
shows the NNT in various scenarios for targeted HCV-
testing, based on the analytic sample.
All three anti-HCV positive individuals without known
HIV infection–aged 24, 28, and 60 years–denied both
IDU (no missing responses, see above) and NIDU, reported
no history of blood transfusion prior to 1985, fisting, group
sex (proxy measure), lesion-prone STIs, or engaging in
“hard” sexual practices that may lead to bleeding. The
two younger men reported being tattooed, and the indi-
vidual with the active HCV infection had been tattooed
abroad–possibly in the Czech Republic, his country of
origin. (The HCV prevalence in the Czech Republic is
estimated to be 1.5%-2.0% [2]).
Factors associated with lifetime HCV-prevalence
In a univariable analysis (Table 2; n = 840), the following
factors were significantly associated with anti-HCV sero-
positivity: being diagnosed with HIV (OR = 72.7), being
tattooed (OR = 10.4), NIDU of cocaine/amphetamines
(OR = 8.8), and non-Swiss origin (OR = 8.5). None of
the four individuals co-infected with HIV and HCV
(0.5% or the analytic sample) was of Swiss origin, but came
from Brazil, China, Spain, and Italy, countries where HCV
is more prevalent than in Switzerland [2,36].
In the univariable analysis among non-HIV-diagnosed
MSM (Table 2), being tattooed was marginally associated
with HCV infection (OR = 8.3).
No significant associations were found between HCV-
antibody positivity and age, past blood transfusions, being
pierced or genitally pierced, IDU, number of sexual part-
ners, number of UAI partners, UAI episodes, fisting, other
“hard” sexual practices that may lead to bleeding, group
sex (proxy measure), syphilis, or lesion-prone STIs.
Discussion
Prevalence of HCV and lack of evidence for sexual
transmission among non-HIV-diagnosed MSM
In a sample of 821 non-HIV-diagnosed MSM recruited
at a gay health centre in Zurich (Switzerland), we found
an anti-HCV prevalence of 0.37% (0.12-1.69%); and a
prevalence of active (acute or chronic) HCV infection of
0.12% (0.02-0.69%). To our knowledge, this is the first
study to look at the prevalence of hepatitis C among
non-HIV-diagnosed MSM in Switzerland. Although the
level of reported sexually risky behaviours (UAI with dif-
ferent types of partners, numbers of sexual partners) and
related indicators such as lifetime history of gonorrhoea
and syphilis was substantial and comparable with other
surveys on MSM in Switzerland [40], we found no evidence
for elevated rates of sexual transmission of HCV in this
population. Instead, being tattooed was marginally associ-
ated with a positive HCV serostatus, even when controlling
for potential confounding factors. However, questions have
been raised as to whether such associations might be due
to residual confounding, as for low HCV-endemic countries
such as Switzerland strict hygiene guidelines for tattoo and
piercing studios have been implemented [41].
Overall, our results correspond well with previously
published prevalence estimates from Sydney (Health in
Men study), where 7 out of 824 HIV-negative men aged
Schmidt et al. BMC Public Health 2014, 14:3 Page 4 of 11
http://www.biomedcentral.com/1471-2458/14/3
Table 1 Hepatitis C prevalence, socio-demographic, behavioural, and sexual health related sample characteristics,
stratified by HIV diagnosis, in a sample of men who have sex with men from Zurich
Characteristic Total No known HIV infection HIV diagnosed
n = 840 n = 821 n = 19
Hepatitis C prevalence % (95%-CI) n % (95%-CI) n % (95%-CI) n
Antibody* 0.8 (0.4-1.7) 7 0.4 (0.12-1.1) 3 21.1 (8.5-43.3) 4
Antigen* 0.2 (0.1-0.9) 2 0.1 (0.02-0.7) 1 5.3 (0.9-24.6) 1
Age Years Years Years
Range 17-79 17-79 19-59
25%-, 50%-, 75%-quartiles 26, 33, 41 26, 33, 41 33, 38, 47
Country of origin % (95%-CI1) n % (95%-CI) n % (95%-CI) n
By nationality
Swiss 70.4 (67.2-73.3) 591 70.6 (67.4-73.6) 580 57.9 (36.3-76.9) 11
Non-Swiss 21.2 (18.6-24.1) 178 21.0 (18.3-23.9) 172 31.6 (15.4-54.0) 6
Unknown 8.5 (6.8-10.5) 71 8.4 (6.7-10.5) 69 10.5 (2.9-31.4) 2
By national HCV prevalence2
< 1.5% 3.5 (2.4-4.9) 29 3.3 (2.3-4.7) 27 10.5 (2.9-31.4) 2
1.5-3.5% (incl. Switzerland) 87.0 (84.6-89.1) 731 87.3 (84.9-89.4) 717 73.7 (51.2-88.2) 14
> 3.5% 1.1 (0.6-2.0) 9 1.0 (0.5-1.9) 8 5.3 (0.9-24.6) 1
Unknown 8.5 (6.8-10.5) 71 8.4 (6.7-10.5) 69 10.5 (2.9-31.4) 2
Blood exposures Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
Blood transfusion before 1985 1.3 (0.7-2.4) 11 1.4 (0.8-2.4) 11 0.0 (0.0-16.8) 0
Piercing 24.7 (21.8-27.8) 198 24.5 (21.6-27.7) 192 31.6 (15.4-54.0) 6
Performed abroad 6.1 (4.6-7.9) 51 6.0 (4.5-7.8) 49 10.5 (2.9-31.4) 2
Genital piercing 2.8 (1.8-4.2) 22 2.7 (1.8-4.1) 21 6.2 (1.1-28.3) 1
Tattoo 19.9 (17.2-23.0) 145 19.6 (16.8-22.7) 139 35.3 (17.3-58.7) 6
Performed abroad 7.9 (6.2-9.9) 66 7.7 (6.0-9.7) 63 15.8 (5.5-37.6) 3
Current drug use Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
IDU3 3.3 (2.2-5.0) 22 3.1 (2.0-4.7) 20 13.3 (3.7-37.9) 2
NIDU of cocaine / amph.4* 13.6 (11.3-16.3) 99 12.8 (10.6-15.5) 91 47.0 (26.2-69.0) 8
Ecstasy* 12.2 (10.0-14.8) 87 11.8 (9.6-14.4) 82 31.3 (14.2-55.6) 5
Cannabis* 20.4 (17.6-23.4) 151 19.8 (17.1-22.9) 144 46.7 (24.8-69.9) 7
Any of the above* 50.0 (46.6-53.4) 412 48.9 (45.5-52.4) 394 94.7 (75.4-99.1) 18
(Continued) Total No known HIV infection HIV diagnosed
n = 840 n = 821 n = 19
Sexual partners last year Number Number Number
Range 0-500 0-500 0-200
25%-, 50%-, 75%-quartiles 4, 6, 15 4, 6, 12 10, 20, 50
Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
More than 10 sexual partners* 30.1 (27.1-33.3) 250 29.2 (26.2-32.4) 237 68.4 (46.0-84.6) 13
UAI5 partners last year Number Number Number
Range 0-200 0-60 0-200
25%-, 50%-, 75%-quartiles 0, 1, 1 0, 1, 1 0, 1, 6
Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
More than 10 UAI partners* 1.1 (0.6-2.0) 9 0.6 (0.3-1.4) 5 21.1 (8.5-43.3) 4
UAI episodes last year Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
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18-75 years (0.85%) tested positive for HCV antibodies
[42]. As in the Australian study, we found no associa-
tions between HCV seropositivity and sexual practices
that could have plausibly facilitated blood exposure,
such as UAI and fisting. However, in a later longitu-
dinal analysis, the Australian researchers found five
HIV-negative men who seroconverted to HCV positivity
(incidence of 0.11 per 100 person-years). Only one sero-
converter reported IDU, four reported sexual contact
with HIV-positive men, and two had an incident ulcera-
tive sexually transmitted infection [43].
In the Montreal-based Omega cohort study of HIV-
negative MSM, despite an anti-HCV baseline prevalence
of 2.9%, only 1 seroconversion was identified (incidence
of 0.038 per 100 person-years), and this infection could
be attributed to IDU. The authors concluded that sexual
transmission of HCV among non-HIV-diagnosed MSM
appeared to be rare in 2001 [44]. Based on 1,699 non-
IDU MSM recruited in public health clinics in Seattle,
San Diego, and New York City, a low (1.5%) prevalence
of anti-HCV did not “support routine HCV testing of
all MSM” [45].
In a recent study conducted in London, the anti-HCV
prevalence among 965 HIV-negative men was 1.2%
(0.6-2.1%) and thus “higher, but not significantly higher,
than that in the general population (0.67%)” [46]. Although
the prevalence estimate among HIV-negative men in
London was three times higher than in our Zurich sample,
Table 1 Hepatitis C prevalence, socio-demographic, behavioural, and sexual health related sample characteristics,
stratified by HIV diagnosis, in a sample of men who have sex with men from Zurich (Continued)
With steady partner* 48.5 (45.1-52.0) 384 49.1 (45.6-52.6) 380 23.5 (9.6-47.2) 4
With known casual partners 25.1 (22.2-28.2) 201 24.9 (22.0-28.1) 195 33.3 (16.3-56.3) 6
With anonymous partners* 11.8 (9.7-14.3) 92 11.3 (9.3-13.8) 86 31.6 (15.4-54.0) 6
“Hard” sexual practices*6
Any that might lead to bleeding 12.1 (10.1-14.5) 102 11.7 (9.7-14.1) 96 31.6 (15.4-54.0) 6
Fisting, receptive* 4.0 (2.9-5.6) 34 3.8 (2.7-5.3) 31 15.8 (5.5-37.6) 3
Dildo usage, receptive 6.9 (5.4-8.8) 58 6.7 (5.2-8.6) 55 15.8 (5.5-37.6) 3
Anal dilatation, receptive 2.3 (1.5-3.5) 19 2.1 (1.3-3.3) 17 10.5 (2.9-31.4) 2
Enema, receptive 1.2 (0.6-2.2) 10 1.1 (0.6-2.1) 9 5.3 (0.9-24.7) 1
Catheterisation, receptive 1.2 (0.6-2.2) 10 1.2 (0.6-2.2) 10 0.0 (0.0-16.8) 0
With steady partner 6.9 (5.3-8.8) 57 6.7 (5.2-8.6) 54 15.8 (5.5-37.6) 3
With known casual partners 11.3 (9.3-13.6) 94 10.9 (8.9-13.2) 89 26.3 (11.8-48.8) 5
With anonymous partners* 5.9 (4.5-7.7) 49 5.5 (4.2-7.3) 45 21.1 (8.5-43.3) 4
At home 12.6 (10.6-15.1) 105 12.3 (10.2-14.7) 100 26.4 (11.9-48.9) 5
At private sex parties* 4.6 (3.4-6.3) 38 4.2 (3.0-5.8) 34 21.1 (8.5-43.4) 4
In sex clubs* 6.9 (5.4-8.8) 57 6.3 (4.8-8.2) 51 31.6 (15.4-54.0) 6
In cruising areas* 3.4 (2.4-4.9) 28 3.1 (2.1-4.5) 25 15.8 (5.5-37.6) 3
Group sex7* 5.4 (4.0-7.1) 45 4.9 (3.6-6.6) 40 26.3 (11.8-48.8) 5
Lifetime history of STIs8 Valid% (95%-CI) n Valid% (95%-CI) n Valid% (95%-CI) n
Urethral gonorrhea* 20.2 (17.6-23.1) 168 19.6 (17.0-22.5) 159 47.4 (27.4-68.3) 9
Rectal gonorrhea 1.7 (1.0-2.8) 14 1.6 (0.9-2.7) 13 5.3 (0.9-24.7) 1
Pharyngeal gonorrhea 1.5 (0.9-2.6) 13 1.6 (0.9-2.7) 13 0.0 (0.0-16.8) 0
Chlamydial infection* 10.9 (9.0-13.2) 91 10.5 (8.6-12.8) 85 31.6 (15.4-54.0) 6
Syphilis* 8.1 (6.4-10.1) 68 7.1 (5.5-9.1) 58 52.6 (31.7-72.6) 10
Hepatitis A 2.2 (1.4-3.4) 18 2.0 (1.2-3.2) 16 10.5 (2.9-31.4) 2
Hepatitis B* 2.3 (1.5-3.5) 19 1.8 (1.1-3.0) 15 21.1 (8.5-43.4) 4
Genital herpes 2.5 (1.6-3.8) 21 2.4 (1.6-3.7) 20 5.3 (0.9-24.7) 1
Genital or anal warts* 7.8 (6.2-9.8) 65 7.2 (5.6-9.2) 59 31.6 (15.4-54.0) 6
Lesion-prone STIs9* 18.2 (15.8-21.0) 153 17.2 (14.7-19.9) 141 63.2 (41.1-80.9) 12
*Fisher’s exact test <0.05; 1CI: confidence interval; 2National HCV prevalence according to Modh Hanafiah et al. 2012 [36]; 3IDU: injection drug use; 4NIDU of
cocaine/amph.: non-injection drug use of cocaine or amphetamines; 5UAI: unprotected anal intercourse; 6“Hard” sexual practices that may lead to bleeding; 7group
sex: defined as reporting 10 or more sexual partners in the past 12 months and engaging in “hard” practices (see above) in sex clubs or at private sex parties;
8STIs: sexually transmitted infections; 9Lesion-prone STIs: syphilis, rectal gonorrhoea, or chlamydial infection.
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the authors recommend selective, not routine, HCV-testing
among MSM according to the individual risk profile.
A recently published systematic review of studies on
HCV-incidence among MSM concluded that the pooled
incidence measure for HIV-negative MSM “is low and
approximates that seen in the heterosexual population,
where screening is not recommended” [47]. The authors
further suggest validating “the use of factors, such as
at-risk sexual behaviour and the serology of sexual
partners which are not always considered in medical
assessments for targeting routine HCV-screening in
HIV-negative MSM populations”.
In the Australian Trial in Acute Hepatitis C (ATAHC),
sexual transmission among HIV-uninfected individuals
“was unusual but was almost always in the context of
contact with a known HCV-infected partner” [48].
Multiple studies have investigated the associations be-
tween HCV and UAI to identify possible routes of HCV
transmission, producing divergent results. Although sig-
nificant associations between UAI and HCV infection in
MSM have been reported, the validity of some of these
studies [19] is limited by a lack of adjustment for con-
founding behavioural factors. A recent prospective longi-
tudinal cohort study [24] found a significant association
between UAI and HCV infection, but did not include
potential confounders that could explain other sexual or
non-sexual routes of HCV infection, such as frequency
of anal intercourse, group sex, sex-associated bleeding,
traumatising sexual practices such as fisting, use of PDE-
inhibitors, lesion-prone STIs (i.e. sexual), or (procto-)surgical
interventions [25], tattooing or NIDU (i.e. non-sexual).
We were not able to replicate the commonly reported
association between IDU and HCV infection, as none of
the 22 MSM in our sample reporting IDU tested positive
for HCV antibodies. Given the low number and proportion
(3.3%) of MSM with IDU in the analytic sample, our study
was not sufficiently powered to detect IDU as a risk fac-
tor for hepatitis C. However, the prevalences we found
for current IDU, 3.1% among non-HIV-diagnosed MSM
(95%-CI: 2.0-4.7), and 13.3% among HIV-diagnosed MSM
(3.7-37.9%), are very similar to results from the largest
Swiss MSM sample [40], where the respective values
(IDU in the last 12 months among MSM in Zurich)
were 3.7% and 17.0%.
Existing epidemiological studies on the association
between non-injection drug use (NIDU) and HCV pro-
duced fairly consistent findings, indicating elevated
HCV prevalence (2.3%-17%) in different NIDU sam-
ples. However, it still remains unclear whether HCV in
people with NIDU can be attributed to undisclosed
IDU or other residual confounding [49-51], although
the biologic plausibility of intranasal transmission has
Figure 1 Number needed to test (NNT) to detect one active HCV infection Number needed to test (on a logarithmic scale) to detect
one active HCV infection, in different scenarios for targeted HCV-testing. The two intervals at the top are based prevalence estimates for
the Swiss general population, assuming that 75% of those ever infected develop chronic infection, and each reflecting the respective lower and
upper limit. The remaining eleven point estimates with 95% confidence intervals represent MSM recruited at Checkpoint Zurich, reflecting the
whole sample (n = 840; thus including 19 men with diagnosed HIV) or sub-samples based on individual characteristics. (1) Estimate based on
blood donors and pregnant women [2]; (2) Estimate based on mathematical modelling [3]; (3) High anti-HCV prevalence (>3.5%) countries were
defined according to Modh Hanafiah et al. 2012 [36]; (4) Non-injection drug use (NIDU) of cocaine/amphetamines; (5) Any of the following: NIDU
of cocaine/amphetamines, being tattooed, being pierced, receptive fisting, group sex (proxy measure), or a history of lesion-prone STIs
(proxy measure); (6-7) Birth cohort screening (1955-1974/1955-1984) as discussed as add-on strategies by Bruggmann et al. 2013 [39].
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been demonstrated [52-55]. In our sample NIDU of co-
caine/amphetamines had substantial interaction with
known HIV infection; and although none of the HCV-
infected MSM without HIV diagnosis reported NIDU
of snorting drugs, we cannot rule out that this behav-
iour constitutes an independent risk factor for HCV
infection. Again, these findings highlight the need for
further research in this area with more rigorous meth-
odology needed to disentangle the specific pathways
and risk factors for transmission.
With respect to HCV transmission among MSM–sexual
or non-sexual–little attention has been given to the influ-
ence of social and sexual networks [56-58]. Particularly for
gay men living with HIV, such networking has been de-
scribed as serosorting, a practice sometimes conceptualised
as a strategy to reduce HIV transmission risk. However, a
more important motive for HIV-positive MSM to estab-
lish sexual contacts preferably with HIV-seroconcordant
partners is to reduce stigma and sexual rejection [59]. This
consequently leads to a higher chance of exposure to STIs
[60,61]. With respect to hepatitis C it has further been
hypothesised that “assortative mixing, or partnership for-
mation within subgroups, is common and that this mixing
pattern might result in HCV being more prevalent” [62].
We hypothesize that sexual and social networks of MSM
are the key to understanding the dynamics of sexual as well
as non-sexual transmission of HCV. Taking into account
networks and sub-group formation would in our view help
to explain why HCV among HIV-positive MSM has spread
so rapidly in the last decade [24]. This would also explain
why the HCV epidemic among HIV-positive MSM has not
jumped to MSM without HIV diagnosis, despite individual
behaviour that would facilitate HCV transmission in other
sub-populations or networks.
Number needed to test and targeted HCV-testing
The number of non-HIV-diagnosed MSM Checkpoint
clients needed to test in order to detect one active HCV
Table 2 Exposure risks with significant associations comparing HCV antibody positive and negative men who have sex
with men from Zurich, stratified by HIV diagnosis
Factor (exposure risk) HCV pos.1 HCV neg. Fisher’s2 OR3 95% CI4
of OR(Without substitution of missing values) n % n %
HIV5 diagnosis
Total sample (n = 840) Yes 4 21.1 15 78.9 0.000 72.70 14.95-353.56
No 3 0.4 818 99.6
Non-Swiss origin
Total sample (valid n = 769) Yes 5 2.8 173 97.2 0.009 8.51 1.64-18.75
No 2 0.3 589 99.7
No known HIV infection (valid n = 752) Yes 1 0.6 171 99.4 0.542 1.69 0.15-18.75
No 2 0.3 578 99.7
HIV diagnosed (valid n = 17) Yes 4 66.7 2 33.3 0.006 n.a.7
No 0 0.0 11 100.0
Tattooed
Total sample (valid n = 727) Yes 5 3.4 140 96.6 0.004 10.36 1.99-53.94
No 2 0.3 580 99.7
No known HIV infection (valid n = 710) Yes 2 1.4 137 98.6 0.100 8.32 0.75-92.43
No 1 0.2 570 99.8
HIV diagnosed (valid n = 17) Yes 3 50.0 3 50.0 0.099 10.00 0.74-135.33
No 1 9.1 10 90.9
NIDU6 of cocaine or amphetamines NIDU only
Total sample (valid n = 727) Yes 4 4.0 95 96.5 0.012 8.77 1.93-39.81
No 3 0.5 625 99.5
No known HIV infection (valid n = 710) Yes 0 0.0 91 100.0 0.621 n.a.
No 3 0.5 616 99.5
HIV diagnosed (valid n = 17) Yes 4 50.0 4 50.0 0.053 n.a.
No 0 0.0 9 100.0
1HCV pos./neg.: positive/negative for antibodies against hepatitis C virus; 2Fisher’s exact test; 3OR: odds ratio; 4CI: confidence interval; 5HIV: human
immunodeficiency virus; 6NIDU: non-injection drug use; 7n.a.: not applicable (division by zero).
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infection (NNT) was 821 (95%-CI: 146-4545). Recent
Swiss publications recommend HCV screening e.g. for
persons who use or have used intranasal drugs, persons
with body piercings or tattoos if performed in poor hy-
gienic environment, and also for men who have sex
with men [32]. Our study, like all other published studies
on HIV-negative MSM, does not support the screening
of MSM without HIV diagnosis for HCV antibodies,
not even if restricted to those with NIDU of cocaine/
amphetamines, tattoos, piercing, receptive fisting, group
sex (proxy measure), or a history of lesion-prone STIs.
The only sub-population where the NNT was significantly
lower than for the general population (Figure 1) were indi-
viduals originating from high prevalence countries, indi-
viduals with HIV diagnosis (though not significant due to
small numbers), and individuals who reported having been
tattooed or pierced abroad. Other authors have suggested
further evaluating birth cohort screening for HCV [39].
None of the suggested birth cohorts, when applied to our
Zurich sample of MSM, resulted in a NNT lower than for
the general population.
Limitations
Several study limitations need to be considered: First,
the cross-sectional study design precludes the calcula-
tion of incidence rates and the investigation of causation,
as it is uncertain whether reported behaviour preceded
HCV infection or not. Second, as information on HIV
diagnosis was based on self-report, the true HIV preva-
lence among participants is likely to be underestimated.
Unfortunately, as anonymous testing was part of our study
design, the serological test results could not be added
post-hoc. However, focusing on MSM without serologic-
ally confirmed HIV serostatus reflects much better the
situation of health care providers and counsellors when
deciding whom to offer HCV-screening in a clinical set-
ting. Third, the study has two important selection biases:
MSM recruited predominantly at a gay health centre with
a focus on STI services, or at sexual venues, respectively,
are likely to over-represent individuals at higher risk
for acquiring STIs. However, because HCV-testing was
primarily offered to MSM anonymously testing for
HIV and/or syphilis, both HIV-positive MSM as well as
those with past Syphilis infection are likely to be under-
represented in the sample. Also, HIV-diagnosed MSM with
known active or past HCV-co-infection were not included
in our sample. Fourth, given the overall anti-HCV preva-
lence of 0.83% in our sample, this study is not sufficiently
powered to rule out an odds ratio of less than 6.0 for
the association between any potential risk factor and
HCV seropositivity. However, our results on HCV preva-
lence among non-HIV-diagnosed MSM can probably
be generalised to community-based samples of MSM in
Switzerland. Finally, some distortions due to missing data
and misclassifications cannot be excluded. In systematically
screened MSM, urethral, pharyngeal, and rectal manifesta-
tions of gonorrhoea are about equally frequent [63,64],
reflecting sexual practices of men who have sex with
men. In contrast, in our sample, self-reported urethral
gonorrhoea (19.6%) was more than ten times more
common than pharyngeal (1.6%) or particularly rectal
gonorrhoea (1.6%). This large discrepancy points towards
a substantial under-diagnosis of rectal infections such as
with Gonococci and Chlamydia, as suggested elsewhere
[65]. We therefore believe that the real lifetime history of
“lesion-prone STIs” is substantially higher than suggested
by our proxy measure.
Conclusions
Our findings suggest that in Zurich (Switzerland), preva-
lence of hepatitis C among MSM without diagnosed HIV is
not higher than in the general population, where screening
is not recommended. We found no evidence for elevated
rates of sexual transmission of HCV among MSM without
HIV diagnosis. Further studies are needed to clearly deter-
mine whether the identification of non-sexual exposures
such as NIDU, tattoos or nosocomial exposures other than
blood transfusion should prompt HCV-testing; however
such approaches to increase the detection of hepatitis C
should not only target MSM. Although trends in the spread
of HCV among MSM should be closely monitored, for
example in a national MSM cohort study, we currently
see no reason for promoting routine HCV-testing for MSM
without known HIV infection in Switzerland.
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